Illumina Secures Medicare Reimbursement for Comprehensive Cancer Genomic Test at $2,989 Per Test
核心洞察
The Centers for Medicare and Medicaid Services (搜索) approved reimbursement for Illumina's TruSight Oncology Comprehensive (搜索) test at $2,989.55 per test, effective January 1.
The FDA-approved test analyzes over 500 genes to inform cancer treatment decisions, expected to enhance adoption of comprehensive genomic profiling across U.S. healthcare systems.
Approximately 60% of Illumina's sequencing consumables revenue was attributed to clinical customers last year, positioning the company to benefit from increased test utilization.
Illumina Inc. has secured a significant milestone in precision oncology with the Centers for Medicare and Medicaid Services (搜索) (CMS) approving reimbursement for its FDA-approved TruSight Oncology Comprehensive (搜索) test at $2,989.55 per test, effective January 1. The decision creates a national pathway for Medicare coverage of comprehensive genomic profiling in cancer care, potentially transforming access to precision medicine diagnostics.
Comprehensive Genomic Profiling Gains Medicare Coverage
The TruSight Oncology Comprehensive (搜索) test assesses over 500 genes to inform treatment decisions, promoting broader access to precision oncology diagnostics across various healthcare settings. The reimbursement decision is expected to enhance the adoption of comprehensive genomic profiling in the U.S. healthcare system, enabling more laboratories to deliver clinically actionable results to cancer patients.
This development comes at a crucial time for Illumina, as approximately 60% of the company's sequencing consumables revenue was attributed to clinical customers last year. The Medicare reimbursement is anticipated to drive growth by removing a significant barrier to test adoption in clinical settings.
Market Response and Financial Performance
Following the reimbursement announcement, Illumina shares climbed 2.52% to $145.22, reflecting investor optimism about the commercial potential of the decision. The stock is currently trading 2.65% above its 12-month moving average, with shares having increased 2.9% over the past 12 months.
The company has experienced a notable 50.11% three-month share price return, though this comes after a challenging five-year period that resulted in a 63.74% total shareholder return loss for long-term holders.
Analyst Outlook and Valuation Metrics
Analysts have responded positively to the reimbursement news, with several firms raising their price targets. Recent analyst actions include TD Cowen (搜索) raising its target to $140.00 with a Hold rating, Guggenheim (搜索) increasing its target to $144.00 with a Buy rating, and Canaccord Genuity (搜索) setting a $130.00 target with a Hold rating.
The stock carries a neutral rating with an average price target of $130.24 among analysts. Looking ahead to the next earnings report scheduled for February 5, 2026, analysts estimate earnings per share of $1.22, up from $0.95 year-over-year, while revenue is projected to remain flat at $1.10 billion.
Valuation Considerations
Illumina currently trades at a premium P/E multiple of 31.8x, with analysts expecting 28% earnings growth that may justify the current valuation. However, valuation assessments present mixed signals, with one analysis suggesting the stock is 13.8% overvalued at $150.28 compared to a fair value estimate of $132.06, while a discounted cash flow model indicates the shares may trade at a discount to an estimated future value of $181.18.
The company's Benzinga Edge scorecard reveals a "High-Flyer" setup with strong momentum (86.32/100) and growth (82.49/100) scores, though quality (4.59/100) and value (18.92/100) metrics raise concerns about the balance sheet and premium pricing relative to peers.